Calypte HIV test for same-day use cleared in US:
This article was originally published in Clinica
The US FDA has cleared Calypte Biomedical's serum HIV-1 assay for same-day (five-hour response) use, supplementing its existing licence under which it can be sold as an overnight test. The assay confirms the presence of HIV-1 antibodies in serum by Western blotting. Calypte, of Alameda, California, assigned Carter-Wallace the exclusive US marketing rights for the test in September. It also appointed distributors for 13 countries in Asia, Eastern Europe and the Middle East.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.